David A. Ramies

5.0k total citations · 2 hit papers
37 papers, 3.8k citations indexed

About

David A. Ramies is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, David A. Ramies has authored 37 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in David A. Ramies's work include Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (8 papers). David A. Ramies is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (8 papers). David A. Ramies collaborates with scholars based in United States, Canada and United Kingdom. David A. Ramies's co-authors include Roy S. Herbst, David H. Johnson, Bruce E. Johnson, Vincent A. Miller, Alan Sandler, Pam Klein, Hai T. Tran, Róbert Hermann, Mark G. Kris and Diane Prager and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

David A. Ramies

35 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Roy S. Herbst, Bruce E. Johnson et al. Journal of Clinical Oncology profile →
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 1.2k citations David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Ramies United States	18	2.9k	2.7k	1.2k	608	316	37	3.8k
Venice Archer United Kingdom	9	3.6k 1.3×	3.6k 1.3×	919 0.8×	663 1.1×	214 0.7×	16	4.6k
Anh T. Le United States	20	2.3k 0.8×	2.1k 0.8×	1.4k 1.1×	869 1.4×	491 1.6×	56	3.5k
Courtney Hyland United States	2	2.1k 0.7×	2.0k 0.8×	1.9k 1.6×	683 1.1×	398 1.3×	4	3.6k
Andrew Weickhardt Australia	23	2.3k 0.8×	2.3k 0.9×	967 0.8×	527 0.9×	393 1.2×	111	3.4k
Dae Ho Lee South Korea	27	2.9k 1.0×	2.4k 0.9×	940 0.8×	587 1.0×	185 0.6×	91	3.4k
Mark S. Huberman United States	30	3.3k 1.2×	3.0k 1.1×	1.2k 1.0×	778 1.3×	353 1.1×	80	4.5k
Maximiliano Van Kooten Argentina	9	3.7k 1.3×	3.3k 1.2×	1.1k 0.9×	623 1.0×	171 0.5×	14	4.5k
Davey B. Daniel United States	19	2.1k 0.7×	2.2k 0.8×	538 0.4×	688 1.1×	237 0.8×	82	3.3k
Hong‐Hong Yan China	31	2.8k 1.0×	2.5k 0.9×	870 0.7×	866 1.4×	197 0.6×	133	3.7k
Viola W. Zhu United States	30	2.1k 0.8×	1.7k 0.6×	1.0k 0.8×	646 1.1×	283 0.9×	83	2.6k

Countries citing papers authored by David A. Ramies

Since Specialization

Citations

This map shows the geographic impact of David A. Ramies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Ramies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Ramies more than expected).

Fields of papers citing papers by David A. Ramies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Ramies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Ramies. The network helps show where David A. Ramies may publish in the future.

Co-authorship network of co-authors of David A. Ramies

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Ramies. A scholar is included among the top collaborators of David A. Ramies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Ramies. David A. Ramies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cho, Byoung Chul, Melissa L. Johnson, Jair Bar, et al.. (2023). 655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC). Annals of Oncology. 34. S460–S461. 5 indexed citations

Sharma, Shringi, Xavier Pépin, Haran Burri, et al.. (2022). Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors. Clinical Pharmacology in Drug Development. 11(11). 1294–1307. 14 indexed citations

Sharma, Shringi, Xavier Pépin, Haran Burri, et al.. (2021). New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS). Blood. 138(Supplement 1). 4365–4365. 8 indexed citations

Phillips, Tycel, Mark W. Brunvand, Andy I. Chen, et al.. (2021). Safety and Efficacy of Polatuzumab Vedotin + Obinutuzumab for Relapsed/Refractory NHL: A Phase 1b/2 Study. SSRN Electronic Journal.

Atallah, Ehab, Samer K. Khaled, Brenda Cooper, et al.. (2020). Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.. Journal of Clinical Oncology. 38(15_suppl). 7556–7556. 3 indexed citations

Hellerstedt, Beth A., Nicholas J. Vogelzang, Harriet M. Kluger, et al.. (2018). Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma. Clinical Lung Cancer. 20(2). 74–81.e1. 18 indexed citations

Keng, Michael, Samer K. Khaled, Brenda Cooper, et al.. (2018). Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS). Blood. 132(Supplement 1). 4362–4362. 2 indexed citations

Bellmunt, Joaquim, Sumanta K. Pal, Joel Picus, et al.. (2017). Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 4540–4540. 10 indexed citations

Nguyen, Linh T., Jaymes Holland, David A. Ramies, et al.. (2016). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. The Journal of Clinical Pharmacology. 56(9). 1130–1140. 46 indexed citations

10.

Gordon, Michael S., Harriet M. Kluger, Geoffrey I. Shapiro, et al.. (2012). Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 30(15_suppl). 8531–8531. 17 indexed citations

11.

Choueiri, Toni K., Sumanta K. Pal, David F. McDermott, et al.. (2012). Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. Journal of Clinical Oncology. 30(15_suppl). 4504–4504. 35 indexed citations

12.

Hellerstedt, Beth A., Gerald M. Edelman, Nicholas J. Vogelzang, et al.. (2012). Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 30(15_suppl). 7514–7514. 24 indexed citations

13.

Choueiri, Toni K., Sumanta K. Pal, David F. McDermott, et al.. (2012). Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. Journal of Clinical Oncology. 30(5_suppl). 364–364. 13 indexed citations

14.

Buckanovich, Ronald J., Raanan Berger, Avishay Sella, et al.. (2011). Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 29(15_suppl). 5008–5008. 36 indexed citations

15.

Choueiri, Toni K., Sumanta K. Pal, Maria E. Cabanillas, et al.. (2011). Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC).. Journal of Clinical Oncology. 29(15_suppl). e13042–e13042. 7 indexed citations

16.

Ramies, David A., Alan Sandler, Robert J. Gray, et al.. (2007). Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 7634–7634. 2 indexed citations

17.

Eberhard, David A., Bruce E. Johnson, Lukas C. Amler, et al.. (2005). Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. Journal of Clinical Oncology. 23(25). 5900–5909. 1200 indexed citations breakdown →

18.

Herbst, Roy S., David H. Johnson, Eric D. Mininberg, et al.. (2005). Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 23(11). 2544–2555. 452 indexed citations

19.

Messersmith, Wells A., Daniel A. Laheru, Neil Senzer, et al.. (2004). Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774). Clinical Cancer Research. 10(19). 6522–6527. 68 indexed citations

20.

Steadman, Randolph H., Douglas P. Blackall, Lawrence D. Petz, Paul D. Mintz, & David A. Ramies. (2002). Pathogen Inactivation of Plasma Using S-59 and UVA Light Is Efficacious and Well Tolerated in Liver Transplant Surgery - The STEP AC Trial. Anesthesiology. 96(Sup 2). A453–A453. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact